Innovation & Excellence

Leading Innovation in Precision Genomics

At Rophevac, our Research & Development is at the heart of everything we do. We are committed to pioneering innovative genomic solutions that transform healthcare and improve patient outcomes across India and globally.

Data Science & AI

Harnessing artificial intelligence and machine learning for genomic insights

AI in Target Discovery & Validation

Machine learning on multi-omic datasets for target identification, protein structure prediction, and in silico validation.

Learn More

AI-Powered Variant Interpretation

Automated variant classification using VarMiner and OncoMiner platforms with ACMG/AMP guidelines.

Learn More

AI in Biomarker Discovery

Multi-omic integration and predictive biomarkers for treatment response and disease progression.

Learn More

Digital Pathology & AI

AI-powered image analysis with quantitative continuous scoring for biomarker assessment and tissue analysis.

Learn More

AI in Clinical Trial Optimization

Patient recruitment, adaptive trial designs, and real-time monitoring using artificial intelligence.

Learn More

Drug Response Prediction

Pharmacogenomics and cancer treatment selection using AI-driven molecular profiling.

Learn More

Natural Language Processing in Genomics

Scientific literature mining and clinical note analysis for evidence extraction and phenotype identification.

Learn More

AI/ML Infrastructure

Unified data platform, cloud computing, machine learning platforms, and bioinformatics tools.

Learn More

AI Ethics & Governance

Responsible AI principles, data privacy, and model validation ensuring transparency and fairness.

Learn More

About Rophevac R&D

Rophevac's R&D operations are focused on advancing genetic testing technologies, developing precision medicine solutions, and creating next-generation diagnostic tools that enable early disease detection, accurate diagnosis, and personalized treatment strategies.

200+

Scientific Publications

50+

Patents Filed

500K+

Tests Performed Annually

20-25%

Revenue in R&D